Skip to content
Research/Peptide Therapy/CJC-1295

CJC-1295

compound

preliminary evidencePublic

CJC-1295 is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog, promoting the release of growth hormone from the pituitary gland. This can lead to increased muscle mass, improved recovery, and potentially enhanced longevity by supporting metabolic and regenerative processes.

Category: Peptide TherapyUpdated 7/14/2026

Intelligence Profile

Overview

CJC-1295 is a synthetic peptide designed to stimulate the release of growth hormone (GH) from the pituitary gland. It belongs to a class of compounds known as growth hormone-releasing hormone (GHRH) analogs, which work by mimicking the natural hormone that signals the body to produce growth hormone. Originally developed for potential therapeutic applications, CJC-1295 has gained attention in recent years within the performance enhancement and longevity communities due to its ability to potentially increase growth hormone levels without the need for direct GH injection.

The compound has been studied in clinical settings, including a Phase 2 trial for HIV patients with visceral obesity, though this study was terminated before completion. Current research interest centers around CJC-1295's potential applications in sports medicine, aesthetic treatments, and anti-aging interventions, as part of the broader emerging landscape of peptide therapies. However, much of the current use occurs outside of approved medical contexts, with individuals self-administering the compound based on theoretical benefits rather than established clinical evidence.

From a longevity and health optimization perspective, CJC-1295 matters because growth hormone plays important roles in muscle maintenance, fat metabolism, bone density, and overall metabolic function—all factors that typically decline with age. Proponents suggest that maintaining higher GH levels through compounds like CJC-1295 could potentially support healthy aging, though robust long-term safety and efficacy data from controlled clinical trials remain limited. The gap between theoretical benefits and proven clinical outcomes represents a significant consideration for anyone evaluating this therapy.

Biohacker actions
Check interactionsView protocols

Deep dive

Intelligence Profile

AI-EnrichedUpdated Jul 14, 2026

The Science

Mechanism of Action

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate growth hormone (GH) release from the pituitary gland. However, the specific molecular mechanisms by which CJC-1295 operates are not detailed in the available evidence.

The provided research papers discuss CJC-1295 within the broader context of performance-enhancing peptides that modulate the GH-IGF1 axis, but they do not provide explicit mechanistic details about how CJC-1295 functions at the molecular or physiological level. The studies focus primarily on clinical applications, safety considerations, and regulatory aspects of peptide therapies rather than their underlying biochemical mechanisms.

One clinical trial (NCT00267527) investigated CJC-1295 in HIV patients with visceral obesity, but this study was terminated and does not provide mechanistic insights from its results.

Evidence Limitation: The current evidence base lacks detailed molecular and physiological mechanism data for CJC-1295. While it is classified among peptides affecting the GH-IGF1 axis, the specific pathways, receptor interactions, and downstream effects require additional research to be fully characterized.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional for any medical decisions.

Clinical Applications

CJC-1295 is a synthetic peptide that modulates the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis. Based on available evidence, clinical applications remain limited and largely investigational.

Investigated Medical Applications

HIV-Associated Lipodystrophy: The most documented clinical trial (NCT00267527) evaluated CJC-1295 specifically for treating visceral obesity in HIV patients. However, this Phase 2 study was terminated, and no efficacy or safety results from this trial are publicly available in the provided evidence.

Off-Label and Investigational Uses

Current literature suggests CJC-1295 is being explored across several areas, though robust clinical evidence remains limited:

Sports Medicine and Performance: Multiple 2026 reviews indicate CJC-1295 is used in sports medicine contexts, particularly for musculoskeletal injuries and athletic performance enhancement. However, these sources emphasize the gap between clinical evidence and actual patient use, noting that many applications lack sufficient safety and efficacy data.

Anti-Aging and Metabolic Applications: Recent reviews mention CJC-1295's use in aesthetic medicine, metabolic conditions, and gerontology applications focused on healthy aging. The therapeutic rationale centers on its ability to stimulate growth hormone release, potentially addressing age-related GH decline.

Orthopedic Applications: Some literature references its use in orthopedic and musculoskeletal contexts, though specific clinical outcomes data is not detailed in the available evidence.

Evidence Limitations

The current evidence base reveals significant gaps between theoretical applications and proven clinical efficacy. Multiple reviews from 2026 consistently highlight concerns about the use of GH-modulating peptides like CJC-1295, noting limited clinical trial data, safety questions, and regulatory challenges. The terminated HIV study represents the only identified formal clinical trial, providing no outcome data.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. CJC-1295 remains largely investigational, and patients should consult qualified healthcare providers regarding any peptide therapy considerations.

Safety Profile

Safety Profile of CJC-1295

Evidence Limitation Notice: The available evidence for CJC-1295 safety is limited, consisting primarily of narrative reviews and one terminated clinical trial. No completed randomized controlled trials with comprehensive safety data were identified.

Known Side Effects

The evidence base for CJC-1295 side effects is thin. Available literature consists mainly of review articles that do not provide specific adverse event data from controlled studies. The single identified clinical trial (NCT00267527) investigating CJC-1295 in HIV patients with visceral obesity was terminated, and safety outcomes from this study are not available in the provided evidence.

Contraindications

No specific contraindications for CJC-1295 are established in the available evidence. This represents a significant knowledge gap given the compound's mechanism of action on the growth hormone-IGF-1 axis.

Drug Interactions

The provided evidence does not contain information about drug interactions with CJC-1295. This lack of data is concerning given that the compound affects hormone pathways that could potentially interact with other medications.

Populations That Should Exercise Caution

While specific safety data is lacking, the following populations may be at increased risk based on CJC-1295's mechanism of action on growth hormone pathways:

  • Individuals with active malignancies (theoretical concern due to IGF-1's growth-promoting effects)
  • Patients with diabetes (potential effects on glucose metabolism)
  • Individuals with cardiovascular disease
  • Pregnant or breastfeeding women
  • Children and adolescents

Important Note: These precautions are based on theoretical concerns related to growth hormone pathway modulation rather than specific clinical evidence for CJC-1295.

Regulatory Status and Safety Concerns

The available literature indicates that CJC-1295 is used in recreational and professional sports settings, often without medical supervision. Several reviews emphasize safety concerns related to the use of unapproved peptide therapies and highlight the need for more rigorous clinical evidence.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Anyone considering CJC-1295 should consult with a qualified healthcare provider to discuss potential risks and benefits based on their individual medical history and circumstances.

Critical Gap: The termination of the only identified clinical trial and the lack of published safety data represent significant limitations in our understanding of CJC-1295's safety profile. More research is needed to establish appropriate safety guidelines for this compound.

Key Research Papers

Research Papers and Clinical Trials

The available research on CJC-1295 comes primarily from review articles published in 2026 rather than dedicated studies of the compound itself. These reviews examine CJC-1295 within the broader context of peptide therapies and performance-enhancing substances.

Several comprehensive reviews have addressed CJC-1295 as part of the "emerging landscape of performance-enhancing peptides" that target the growth hormone-IGF1 axis. These papers, published in journals including Frontiers in Endocrinology, Sports Medicine, and International Journal of Molecular Sciences, discuss CJC-1295 alongside other peptide therapies in contexts ranging from sports medicine to aesthetic and metabolic applications.

The reviews consistently frame CJC-1295 within discussions of unapproved peptide therapies, noting the gap between limited clinical evidence and widespread patient self-administration. Multiple papers published in JBJS Reviews, The American Journal of Sports Medicine, and The Journal of Sports Medicine and Physical Fitness specifically address CJC-1295's use in athletic performance enhancement and its implications for anti-doping efforts.

Clinical Trial Evidence

Only one clinical trial appears in the available evidence: a Phase 2 study (NCT00267527) that evaluated CJC-1295 in HIV patients with visceral obesity. However, this study was terminated, and no results or sample size information is provided in the available data.

Evidence Limitations

The current evidence base is notably thin. The available literature consists entirely of review articles rather than primary research studies on CJC-1295. No completed clinical trials with published results were identified, and the single registered trial was terminated without apparent completion. This represents a significant gap between the compound's apparent use and the scientific evidence supporting its safety and efficacy.

This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any peptide therapy.

Clinical Protocols

Protocols

Based on the available literature, specific dosing protocols for CJC-1295 are limited in published clinical evidence. The compound has been studied primarily in research settings, with one notable clinical trial (NCT00267527) that was terminated during Phase 2 evaluation in HIV patients with visceral obesity.

The literature indicates that CJC-1295 belongs to a class of growth hormone-releasing peptides that are increasingly being used in sports medicine and aesthetic applications, though much of this use appears to be occurring outside of established clinical protocols.

Evidence Limitations:
The current evidence base lacks detailed, standardized dosing protocols from completed clinical trials. Most references to CJC-1295 administration protocols come from sports medicine reviews and discussions of peptide use in athletic performance contexts, rather than from controlled clinical studies with published dosing guidelines.

Administration Considerations Noted in Literature:

  • CJC-1295 is typically administered via subcutaneous injection
  • The compound is often discussed in combination with other peptides in the growth hormone pathway
  • Safety profiles and optimal dosing remain inadequately characterized due to limited completed clinical trial data

Research Gap:
The termination of the primary clinical trial (NCT00267527) and the lack of other completed studies means that evidence-based dosing protocols are not well-established in peer-reviewed literature. Current use appears to be based largely on anecdotal reports and off-label applications rather than robust clinical evidence.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Any consideration of CJC-1295 therapy should involve consultation with qualified healthcare professionals who can evaluate individual medical circumstances and current regulatory status.

Outcomes & Evidence

Outcomes

The available evidence for CJC-1295 outcomes is extremely limited, consisting primarily of narrative reviews and a single terminated clinical trial. No completed clinical trials with published results were identified in the evidence provided.

Clinical Trial Evidence

The only identified clinical trial (NCT00267527) was a Phase 2 study evaluating CJC-1295 in HIV patients with visceral obesity, but this trial was terminated with no published outcomes data available. This represents a significant gap in direct clinical evidence for the compound's effectiveness.

Literature Review Evidence

The provided studies consist entirely of narrative reviews published in 2026 examining various therapeutic peptides, including CJC-1295, across multiple medical contexts:

  • Performance enhancement and sports medicine applications
  • Aesthetic, metabolic, and endocrine conditions
  • Musculoskeletal injuries and athletic performance
  • Gerontology and healthy aging applications
  • Orthopedic therapeutic uses

However, these reviews do not provide specific measurable outcomes data for CJC-1295 itself. The evidence appears to focus on broader categorizations of peptide therapies rather than compound-specific results.

Evidence Limitations

The strength of evidence for CJC-1295 outcomes is very weak. Key limitations include:

  • No completed clinical trials with published results
  • Absence of specific biomarker changes, symptom improvements, or other measurable outcomes
  • Reviews do not differentiate outcomes between different peptide compounds
  • Lack of controlled studies with quantifiable endpoints

Disclaimer: This summary is for informational purposes only and should not be considered medical advice. Consult with a qualified healthcare provider before considering any peptide therapy.

The current evidence base is insufficient to draw conclusions about CJC-1295's clinical effectiveness or safety profile based on measurable outcomes.